| Literature DB >> 23348691 |
Sarita Saraswati1, S S Agrawal.
Abstract
In this study, we investigated the mechanism of brucine in tumor angiogenesis. We found that brucine inhibits VEGF-induced cell proliferation, chemotactic motility, and the formation of capillary-like structures in HUVECs in a dose-dependent manner. Brucine suppresses VEGF- induced p-VEGFR2 kinase activity and inhibits neovascularization in vivo. Brucine inhibits the downstream protein kinases of VEGFR2, including Src, FAK, ERK, AKT and mTOR. And further downregulates levels of VEGF, NO, IL-6, IL-8, TNF-α and IFN-γ in HUVECs. Taken together, our study suggests that brucine potently suppresses angiogenesis by targeting VEGFR2 activation and may be a viable drug candidate in anti-angiogenesis and anti-cancer therapies.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23348691 DOI: 10.1016/j.canlet.2013.01.012
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679